Amgen, Inc. (AMGN) Stake Boosted by IHT Wealth Management LLC

IHT Wealth Management LLC lifted its holdings in Amgen, Inc. (NASDAQ:AMGN) by 4.2% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 7,494 shares of the medical research company’s stock after purchasing an additional 303 shares during the period. IHT Wealth Management LLC’s holdings in Amgen were worth $1,459,000 as of its most recent filing with the SEC.

Several other institutional investors have also bought and sold shares of AMGN. CapWealth Advisors LLC boosted its holdings in Amgen by 123.1% during the fourth quarter. CapWealth Advisors LLC now owns 28,894 shares of the medical research company’s stock valued at $5,625,000 after purchasing an additional 15,944 shares in the last quarter. Amundi Pioneer Asset Management Inc. boosted its holdings in Amgen by 5.2% during the fourth quarter. Amundi Pioneer Asset Management Inc. now owns 1,538,795 shares of the medical research company’s stock valued at $299,554,000 after purchasing an additional 76,636 shares in the last quarter. Voleon Capital Management LP acquired a new stake in Amgen during the fourth quarter valued at approximately $19,467,000. Municipal Employees Retirement System of Michigan acquired a new stake in Amgen during the fourth quarter valued at approximately $6,504,000. Finally, Miramar Capital LLC acquired a new stake in Amgen during the fourth quarter valued at approximately $3,602,000. Institutional investors and hedge funds own 79.18% of the company’s stock.

Shares of AMGN opened at $177.47 on Friday. The company has a market capitalization of $109.31 billion, a PE ratio of 12.32, a price-to-earnings-growth ratio of 2.17 and a beta of 1.21. The company has a debt-to-equity ratio of 2.36, a quick ratio of 2.57 and a current ratio of 2.79. Amgen, Inc. has a one year low of $165.22 and a one year high of $210.19.

Amgen (NASDAQ:AMGN) last announced its earnings results on Tuesday, January 29th. The medical research company reported $3.42 EPS for the quarter, topping the consensus estimate of $3.26 by $0.16. The business had revenue of $6.23 billion for the quarter, compared to the consensus estimate of $5.88 billion. Amgen had a return on equity of 66.74% and a net margin of 35.35%. During the same period in the previous year, the business earned $2.89 EPS. On average, sell-side analysts expect that Amgen, Inc. will post 13.96 EPS for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Friday, June 7th. Stockholders of record on Friday, May 17th will be issued a $1.45 dividend. This represents a $5.80 annualized dividend and a dividend yield of 3.27%. The ex-dividend date is Thursday, May 16th. Amgen’s payout ratio is currently 40.28%.

In other news, Director Ronald D. Sugar sold 2,000 shares of the business’s stock in a transaction that occurred on Wednesday, March 6th. The stock was sold at an average price of $188.88, for a total value of $377,760.00. Following the transaction, the director now directly owns 14,988 shares of the company’s stock, valued at approximately $2,830,933.44. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders sold a total of 6,000 shares of company stock worth $1,144,120 over the last three months. 0.27% of the stock is owned by company insiders.

A number of equities research analysts have weighed in on AMGN shares. Citigroup lifted their price objective on Amgen from $204.00 to $210.00 and gave the company a “neutral” rating in a report on Friday, January 4th. Zacks Investment Research raised Amgen from a “hold” rating to a “buy” rating and set a $225.00 price objective on the stock in a report on Monday, January 14th. Royal Bank of Canada reaffirmed a “neutral” rating and set a price objective on shares of Amgen in a report on Monday, January 14th. Goldman Sachs Group reaffirmed a “buy” rating and set a $232.00 price objective on shares of Amgen in a report on Thursday, January 17th. Finally, Oppenheimer set a $224.00 price objective on Amgen and gave the company a “buy” rating in a report on Sunday, January 27th. Eleven investment analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. Amgen has a consensus rating of “Hold” and an average target price of $209.11.

WARNING: “Amgen, Inc. (AMGN) Stake Boosted by IHT Wealth Management LLC” was first published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this article on another domain, it was illegally stolen and reposted in violation of US and international trademark & copyright legislation. The legal version of this article can be read at https://www.dispatchtribunal.com/2019/04/21/amgen-inc-amgn-stake-boosted-by-iht-wealth-management-llc.html.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, and neuroscience. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, a pegylated protein to treat cancer patients; Prolia to treat postmenopausal women with osteoporosis; Aranesp to treat anemia; Xgeva for skeletal-related events prevention; Sensipar/Mimpara products to treat sHPT in chronic kidney disease; and EPOGEN to treat a lower-than-normal number of red blood cells.

Recommended Story: Hedge Funds

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen, Inc. (NASDAQ:AMGN).

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.